Yuling Luo rang the Nasdaq closing bell Friday having taken his first company public in a massively oversubscribed round. The Alamar Biosciences CEO’s IPO was one of two back-to-back blockbuster biotech offerings this week, a clear signal that investors are willing to open their wallets for life sciences companies again—under the right conditions.
On Thursday, Kailera Therapeutics, an obesity drug developer, raised $625 million in what is believed to be the largest biotech IPO in Nasdaq history. The IPO priced 39.1 million shares at $16 (the top of its range). The company had initially set out to raise just $500 million. One day post-IPO, Kailera was already up 63 percent.
